We are live on ! Find out more
IPXL

Impax Laboratories, Inc.
IPXL

Delisted

IPXL was delisted on the 4th of May, 2018.

185 hedge funds and large institutions have $1.85B invested in Impax Laboratories, Inc. in 2014 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 66 increasing their positions, 72 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more capital invested

Capital invested by funds: $1.45B → $1.85B (+$402M)

16% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 25

2% more funds holding

Funds holding: 181185 (+4)

8% less repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 72

32% less call options, than puts

Call options by funds: $3.56M | Put options by funds: $5.24M

Holders
185
Holders Change
+4
Holders Change %
+2.21%
% of All Funds
5.31%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
29
Increased
66
Reduced
72
Closed
25
Calls
$3.56M
Puts
$5.24M
Net Calls
-$1.68M
Net Calls Change
-$5.12M
Name Holding Trade Value Shares
Change
Change in
Stake
Barclays
126
Barclays
United Kingdom
$710K +$270K +10,026 +69%
BIM
127
BRC Investment Management
Colorado
$683K -$9.17K -340 -1%
CAM
128
Cortina Asset Management
Wisconsin
$671K -$126K -4,662 -17%
Public Employees Retirement Association of Colorado
129
Public Employees Retirement Association of Colorado
Colorado
$630K
Envestnet Asset Management
130
Envestnet Asset Management
Illinois
$611K -$11K -407 -2%
PIM
131
Partner Investment Management
California
$609K +$547K +20,295 New
TAM
132
Tocqueville Asset Management
New York
$600K +$108K +4,000 +25%
Two Sigma Investments
133
Two Sigma Investments
New York
$576K -$7.42M -275,205 -93%
T. Rowe Price Associates
134
T. Rowe Price Associates
Maryland
$549K
Tudor Investment Corp
135
Tudor Investment Corp
Connecticut
$540K
Los Angeles Capital Management
136
Los Angeles Capital Management
California
$529K -$216K -7,995 -31%
PA
137
Profund Advisors
Maryland
$520K -$56.9K -2,108 -11%
ZIM
138
Zacks Investment Management
Illinois
$501K +$234K +8,672 +108%
OAM
139
Oxford Asset Management
United Kingdom
$484K -$1.37M -50,824 -76%
MERSOM
140
Municipal Employees' Retirement System of Michigan
Michigan
$480K +$8.09K +300 +2%
CLOS
141
Compagnie Lombard Odier SCmA
Switzerland
$467K +$420K +15,580 New
Arrowstreet Capital
142
Arrowstreet Capital
Massachusetts
$463K -$7.23M -267,839 -95%
FP
143
Foundry Partners
Minnesota
$425K -$1.75K -65 -0.5%
SB
144
Suntrust Banks
Georgia
$401K -$157K -5,806 -30%
ONB
145
Old National Bancorp
Indiana
$368K +$331K +12,278 New
SKK
146
Shepherd Kaplan Krochuk
Massachusetts
$328K
PI
147
PineBridge Investments
New York
$305K -$162K -5,997 -37%
Citigroup
148
Citigroup
New York
$283K -$52.4K -1,942 -17%
B
149
Baird
Wisconsin
$278K -$324K -12,005 -56%
IAM
150
Iridian Asset Management
Connecticut
$272K -$101K -3,730 -29%

IPXL Hedge Fund Activity: Q2 2014 in Review

185 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q2 2014, worth a combined $1.85B — up 28% from $1.45B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new IPXL positions and 25 closed out — a net gain of 4 holders — while 66 added to existing stakes and 72 trimmed.

The largest buyer was Invesco, adding an estimated $41.5M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $27.6M sold.

  • 185 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q2 2014, up from 181 in Q1 2014.
  • Funds reported $1.85B of Impax Laboratories, Inc. stock for Q2 2014, up 28% quarter-over-quarter.
  • 29 funds opened new Impax Laboratories, Inc. positions in Q2 2014 and 25 closed out, a net change of +4 holders.
  • The largest Impax Laboratories, Inc. buyer in Q2 2014 was Invesco, an estimated $41.5M added.
  • The largest Impax Laboratories, Inc. seller in Q2 2014 was Renaissance Technologies, an estimated $27.6M sold.

Based on aggregated 13F filings for Q2 2014.